SMAD3 and non-small cell lung carcinoma: These results confirmed that ELK4 is a direct regulator of MSI2 expression and that MSI2 promotes NSCLC progression through TGF‐β/SMAD3 activation, suggesting the potential clinical value of inhibiting MSI2 in NSCLC.